Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Market Cap	1.16Cr 1.33Cr 1.08Cr 1.01Cr 1.89Cr 125.95Cr 1.9Cr 13Cr 4.96Cr 62Cr 5.01Cr 4.9Cr 215.26Cr	P/E 2024	-5.06x	P/E 2025	9.44x
Enterprise Value	99.3L 1.14Cr 91.97L 86.09L 1.61Cr 107.46Cr 1.62Cr 11Cr 4.23Cr 53Cr 4.28Cr 4.18Cr 183.67Cr	EV / Sales 2024	141x	EV / Sales 2025	281x
Free-Float	30.7%	Yield 2024 *	-	Yield 2025	-

15/04	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
02/04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/25/30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
29/25/29	Celyad Oncology announces research facility divestiture	RE
29/25/29	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25/25/25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/25/26	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
29/25/29	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
28/25/28	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25/25/25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
24/25/24	Celyad Oncology Announces Strategic Review	CI
02/25/02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/25/18	Celyad: share price soars on encouraging data

28/22/28	HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading	MT
11/22/11	Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating	MT
06/21/06	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating	MT
26/21/26	CELYAD ONCOLOGY : JonesTrading Downgrades Celyad Oncology to Hold from Buy	MT
08/20/08	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $18 From $22, Keeps Buy Rating	MT

20/05	Celyad Oncology : AGM Minutes - informal translation EN	PU
02/04	Celyad Oncology : reports full year 2025 financial results and business highlights	PU
29/25/29	Celyad Oncology : Announces Research Facility Divestiture	PU
12/25/12	Celyad Oncology SA - Publication of a transparency notification received from Fortress Investment Group LLC	AQ
11/25/11	Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)	PU

20/05	Celyad Oncology : AGO Procès Verbal - version FR
17/04	Celyad Oncology : Rapport Annuel 2025 FR
17/04	Celyad Oncology : Statutory Annual Accounts 2025 FR
17/04	Celyad Oncology : Shareholder Proxy Legal Entities FR / EN
17/04	Celyad Oncology : Shareholder Proxy Natural Persons FR / EN

Celyad SA Share Price Other OTC

Stocks

CLYYF

BE0974260896

Biotechnology & Medical Research

Valuation: Celyad SA

Latest news : Celyad SA

Analysts' recommendations: Celyad SA

Press Releases: Celyad SA

News in other languages: Celyad SA

Quotes and Performance

Managers and Directors: Celyad SA

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
David Georges DFI	Director of Finance/CFO	-	01/01/2019
An Phan LAW	General Counsel	51	01/09/2021

Director	Title	Age	Since
Michel Lussier CHM	Chairman	69	24/07/2007
Serge Goblet BRD	Director/Board Member	-	01/01/2008
Hilde Windels CHM	Chairman	61	23/06/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELYAD SA	-25.25%	-.--%	-	-	1.33Cr
LONZA GROUP AG	+1.44%	+1.71%	-10.63%	-9.16%	4.31TCr
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+308.19%	+562.02%	3.47TCr
BEONE MEDICINES AG	+2.84%	+2.14%	+6.87%	+34.93%	3TCr
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.51%	-22.34%	2.8TCr
CELLTRION, INC.	-1.90%	-1.56%	+11.62%	+19.80%	2.44TCr
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	1.43TCr
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+52.04%	+107.47%	1.31TCr
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.18%	+4.20%	1.25TCr
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+100.27%	+80.69%	1.22TCr
Average	-2.16%	+0.73%	+60.26%	+97.20%	2.36TCr
Weighted average by Cap.	+0.77%	+1.27%	+65.22%	+113.23%

	2024	2025
Net sales	2L 2L 2L 2L 3L 2.01Cr 3L 20.44L 8L 99.08L 8L 8L 3.44Cr	21T 24.09T 19.45T 18.21T 34.15T 22.73L 34.35T 2L 89.42T 11.19L 90.41T 88.47T 38.84L
Net income	-58.24L -66.8L -53.94L -50.49L -94.7L -63Cr -95.27L -6.4Cr -2.48Cr -31Cr -2.51Cr -2.45Cr -107.72Cr	8L 10L 8L 7L 13.5L 8.98Cr 13.58L 91.19L 35.34L 4.42Cr 35.73L 34.97L 15Cr
Net Debt	-32.95L -37.79L -30.52L -28.57L -53.58L -36Cr -53.9L -3.62Cr -1.4Cr -18Cr -1.42Cr -1.39Cr -61Cr	-17.08L -19.59L -15.82L -14.81L -27.77L -18Cr -27.94L -1.88Cr -72.73L -9.1Cr -73.53L -71.96L -32Cr